Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.72 |
| ▸ | POLA1 | P09884 | 1/20 | 0.71 |
| ▸ | OSBP | P22059 | 6/20 | 0.70 |
| ▸ | RORC | P51449 | 4/20 | 0.70 |
| ▸ | OSBP2 | Q969R2 | 3/20 | 0.70 |
| ▸ | USP2 | O75604 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.70 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.60 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.60 |
| ▸ | NR1H3 | Q13133 | 5/20 | 0.60 |
| ▸ | GBA1 | P04062 | 2/20 | 0.59 |
| ▸ | UGCG | Q16739 | 2/20 | 0.59 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.59 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.58 |
| ▸ | NPC1L1 | Q9UHC9 | 2/20 | 0.57 |
| ▸ | CRYAB | P02511 | 1/20 | 0.57 |
| ▸ | HMGCR | P04035 | 1/20 | 0.57 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.57 |
| ▸ | ITGAV | P06756 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21707462 | 1.00 | CYP46A1 (0.72) | CYP46A1POLA1OSBPRORCOSBP2 | |
| SCHEMBL21741490 | 1.00 | CYP46A1 (0.72) | CYP46A1POLA1OSBPRORCOSBP2 | |
| SCHEMBL6569559 | 1.00 | CYP46A1 (0.72) | CYP46A1POLA1OSBPRORCOSBP2 | |
| SCHEMBL728696 | 1.00 | CYP46A1 (0.72) | CYP46A1POLA1OSBPRORCOSBP2 | |
| SCHEMBL1369754 | 0.91 | CYP46A1 (0.75) | CYP46A1POLA1OSBPRORCOSBP2 | |
| SCHEMBL21935259 | 0.91 | CYP46A1 (0.75) | CYP46A1POLA1OSBPRORCOSBP2 | |
| SCHEMBL22523945 | 0.91 | CYP46A1 (0.75) | CYP46A1POLA1OSBPRORCOSBP2 | |
| SCHEMBL7989828 | 0.91 | CYP46A1 (0.75) | CYP46A1POLA1OSBPRORCOSBP2 | |
| SCHEMBL18627850 | 0.91 | CYP46A1 (0.75) | CYP46A1POLA1OSBPRORCOSBP2 | |
| SCHEMBL1045464 | 0.91 | CYP46A1 (0.75) | CYP46A1POLA1OSBPRORCOSBP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102614528-B | Polyconjugates for in vivo delivery of polynucleotides | ARROWHEAD MADISON INC | 2014-02-26 | — | — | CN | disclosed |
| US-8658211-B2 | Polyconjugates for in vivo delivery of polynucleotides | Arrowhead Madison Inc. (US) | 2014-02-25 | — | — | US | disclosed |
| US-20120230938-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | Arrowhead Madison Inc. (US) | 2012-09-13 | — | — | US | disclosed |
| CN-102614528-A | Polyconjugates for in vivo delivery of polynucleotides | ARROWHEAD MADISON INC | 2012-08-01 | — | — | CN | disclosed |
| US-8137695-B2 | Transferring interfering RNA sequences into cells via conjugation with physiologically labile bond associated with polyamine and/or polyvinyl ether | Arrowhead Madison Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| CN-101500548-A | Polyconjugates for in vivo delivery of polynucleotides | HOFFMANN LA ROCHE (CH) | 2009-08-05 | — | — | CN | disclosed |
| EP-2061443-A2 | POLYCONJUGATES FOR IN VIVO DELIVERY OF POLYNUCLEOTIDES | F.HOFFMANN-LA ROCHE AG (CH) | 2009-05-27 | — | — | EP | disclosed |
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | Arrowhead Pharmaceuticals, Inc. | 2008-06-26 | — | — | US | disclosed |
| WO-2008022309-A2 | POLYCONJUGATES FOR IN VIVO DELIVERY OF POLYNUCLEOTIDES | F. HOFFMANN-LA ROCHE AG (US) | 2008-02-21 | — | — | WO | disclosed |
| EP-1478403-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA, INC. (CA) | 2004-11-24 | — | — | EP | disclosed |
| WO-2003063909-A1 | RESPONSIVE MICROGEL AND METHODS RELATED THERETO | SUPRATEK PHARMA INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-0910351-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0907666-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. Searle & Co. (US) | 1999-04-14 | — | — | EP | disclosed |
| WO-1997049736-A2 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
| WO-1997049387-A1 | PARTICLES COMPRISING AMPHIPHILIC COPOLYMERS, HAVING A CROSS-LINKED SHELL DOMAIN AND AN INTERIOR CORE DOMAIN, USEFUL FOR PHARMACEUTICAL AND OTHER APPLICATIONS | G.D. SEARLE AND CO. (US) | 1997-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120230938-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | PHAX, NCL, PCBP1 | CYP46A1 4605/4885POLA1 603/4885OSBP 2965/4885 |
| US-20080152661-A1 | Polyconjugates for In Vivo Delivery of Polynucleotides | PHAX, PCBP1, NCL | CYP46A1 4657/4885POLA1 652/4885OSBP 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.